6,467,802 Shares in Regulus Therapeutics Inc. (NASDAQ:RGLS) Purchased by NEA Management Company LLC

NEA Management Company LLC purchased a new position in Regulus Therapeutics Inc. (NASDAQ:RGLS) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 6,467,802 shares of the biopharmaceutical company’s stock, valued at approximately $10,154,000. Regulus Therapeutics makes up 0.6% of NEA Management Company LLC’s investment portfolio, making the stock its 27th biggest position. NEA Management Company LLC owned approximately 9.87% of Regulus Therapeutics as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of RGLS. Vanguard Group Inc. grew its stake in Regulus Therapeutics by 158.4% during the 1st quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock valued at $2,132,000 after acquiring an additional 453,784 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Regulus Therapeutics during the 2nd quarter valued at about $352,000. The Manufacturers Life Insurance Company purchased a new position in Regulus Therapeutics during the 3rd quarter valued at about $204,000. Tyche Wealth Partners LLC grew its stake in Regulus Therapeutics by 920.6% during the 3rd quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock valued at $167,000 after acquiring an additional 95,694 shares in the last quarter. Finally, Rhumbline Advisers purchased a new position in Regulus Therapeutics during the 2nd quarter valued at about $136,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Trading Down 1.8 %

Shares of Regulus Therapeutics stock opened at $1.61 on Friday. Regulus Therapeutics Inc. has a 52-week low of $1.08 and a 52-week high of $3.79. The stock has a 50-day simple moving average of $1.52 and a 200-day simple moving average of $1.74.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Equities research analysts expect that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on RGLS. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Regulus Therapeutics in a research note on Monday, November 11th. Oppenheimer reaffirmed an “outperform” rating and set a $7.00 target price on shares of Regulus Therapeutics in a research note on Wednesday, August 14th. Finally, StockNews.com raised Regulus Therapeutics to a “sell” rating in a research note on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.80.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.